Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Merck & Co. 16.607, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Merck & Co. vs CSL: Revenue Comparison
Merck & Co. (MRK) and CSL (CSL.AX) are peers in Vaccines. Merck & Co. reported revenue of $16.6B as of Q2 2026, compared with $7.3B for CSL. Merck & Co. leads on revenue.
Merck & Co.'s gross margin is 73.5% versus 44.4% for CSL. Merck & Co.'s net margin is -8.0% versus -40.2% for CSL.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., CSL.| Metric | Merck & Co. | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $16.61B | $7.30B |
| Cost of Revenue | $4.39B | $4.06B |
| Gross Profit | $12.21B | $3.24B |
| Operating Income | $-683.00M | $1.39B |
| Net Income | $-1.33B | $-2.94B |
| R&D Expense | $9.74B | $614.00M |
| Earnings Per Share | -$0.54 | -$6.14 |
| Gross Margin | 73.5% | 44.4% |
| Operating Margin | -4.1% | 19.0% |
| Net Profit Margin | -8.0% | -40.2% |
| Free Cash Flow | $4.48B | $1.76B |
| Cumulative Free Cash Flow | $249.70B | $21.56B |
| Operating Cash Flow | $5.37B | $2.09B |
| Cash & Equivalents | $6.85B | $1.51B |